The transition from prototyping to production is the highest-cost, highest-risk part of new product development. Addifab sells a proprietary platform that yields upfront and recurring revenues while reducing costs, times-to-market and emissions with +75%.
Addifab Freeform Injection Molding speeds up tool iterations with unseen details and tight tolerances. The technology allows manufacturers to reduce early-stage production tool investments and lead-times with +80%. Whether you are a designer, engineer, toolmaker or contract manufacturer, Freeform Injection Molding is your gateway to optimum design freedom while maintaining the strengths of injection molding.
KEY CUSTOMERS AND INTERNATIONAL PRESENCE
Addifab serves manufacturers of injection-molded parts for medical devices, sporting goods, consumer goods, automobiles, packaging solutions and industrial hardware in The United States, Germany, Denmark, Sweden, Belgium, Taiwan and Japan.
Lasse G. Staal is co-founding CEO, with a strong track record in business development and fund-raising. Jon Jessen and Peter L. Sørensen lead innovation, while Peter Jacobsen heads Production and SCM. David Meyer chairs the Addifab Board of Directors.
Unique selling point
Addifab enables injection molders to create faster, cheaper and greener injection mold tooling that breaks design barriers to allow unseen innovation.
Addifab is honored to be collaborating with Mitsubishi Chemical, and to have received an investment from Diamond Edge Ventures. They are in search of distribution partners, funding, clients, and talent recruitment across East Asia.
GET IN TOUCH WITH